Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T18598 |
PROTAC BRD2/BRD4 degrader-1
|
Others | Others |
PROTAC BRD2/BRD4 degrader-1 (compound 15) serves as a potent, selective degrader of BET proteins BRD4 and BRD2, achieving rapid, reversible, and unexpectedly selective elimination of BRD4 and BRD2 compared to BRD3. Its efficacy in suppressing solid tumors manifest with minimal cytotoxic effects. This compound comprises a BET inhibitor, a connecting linker, and thalidomide as the ligand for cereblon (CRBN)/cullin 4A[1]. | |||
T5435 |
ARV-771
|
Epigenetic Reader Domain; PROTACs | Chromatin/Epigenetic; PROTAC |
ARV-771 是基于 PROTAC 技术的有效 BET 降解剂,对 BRD2(1)、BRD2(2)、BRD3(1)、BRD3(2)、BRD4 (1) 和 BRD4(2)的 Kd 分别为 34、4.7、8.3、7.6、9.6 和 7.6 nM。 | |||
T10522 |
BET-IN-6
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BET-IN-6 是一种有效且高亲和力的BRD2/BRD4抑制剂。BET-IN-6 是靶蛋白 BRD2/4 的配体,可用于合成 PROTAC BRD2/BRD4 degrader-1 。 | |||
T74391 |
OARV-771
|
PROTACs | PROTAC |
OARV-771 是一种基于 VHL 的 BET 降解剂 (PROTAC),具有改善的细胞通透性。OARV-771 显示 Brd4、Brd2 和 Brd3的 DC50分别为 6、1 和 4 nM。 | |||
T18808 |
Thalidomide-NH-C4-NH2 TFA
|
Others | Others |
Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2/BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1]. |